Meeting
2022 ASCO Genitourinary Cancers Symposium
FOXP3+ T-cell infiltration is associated with improved outcomes in metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICI).
Authors
Elio Adib
The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA
Elio Adib , Talal El Zarif , Dory Freeman , Muhieddine Labban , Catherine Curran , Bijaya Sharma , Jane Song , Kristen Felt , Amin Nassar , Matthew Davidsohn , Scott J. Rodig , Toni K. Choueiri , David J. Kwiatkowski , Praful Ravi , Guru P. Sonpavde
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 549)
DOI
10.1200/JCO.2022.40.6_suppl.549
Abstract #
549
Poster Bd #
J7
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu
Poster
2022 ASCO Annual Meeting
Comprehensive immune profiling unravels evolution of spatial distribution and immune repertoire in tumor microenvironment from primary to metastatic triple-negative breast cancer.
First Author: Weihua Guo
Poster
2019 ASCO Annual Meeting
Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Updated results.
First Author: Andreas Nicholas Saltos
Poster
2019 Genitourinary Cancers Symposium
Immune infiltrate with CD8 low or PDL1 high associated with metastatic prostate cancer after radical prostatectomy (RP).
First Author: Cecile Vicier